Difference between revisions of "Kaposi sarcoma - null regimens"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "{| class="wikitable" style="width: 100%" to "{| class="wikitable sortable" style="width: 100%") |
m (Text replacement - "style="background-color:#1a9851" |Phase III" to "style="background-color:#1a9851" |Phase 3") |
||
| Line 19: | Line 19: | ||
|[https://doi.org/10.1200/JCO.2005.11.043 Noy et al. 2005 (AMC 013)] | |[https://doi.org/10.1200/JCO.2005.11.043 Noy et al. 2005 (AMC 013)] | ||
|1998-2001 | |1998-2001 | ||
| − | | style="background-color:#1a9851" |Phase | + | | style="background-color:#1a9851" |Phase 3 (C) |
|IM862 | |IM862 | ||
| style="background-color:#91cf60" |Seems to have superior TTP | | style="background-color:#91cf60" |Seems to have superior TTP | ||
Revision as of 02:15, 16 December 2021
The purpose of this page is to provide references to "null therapy" such as placebo and observation. While not clinically relevant, these references provide further insight into the historical development of the treatment landscape. See the main KS page for current regimens.
All lines of therapy
Placebo
| back to top |
Regimen
| Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Noy et al. 2005 (AMC 013) | 1998-2001 | Phase 3 (C) | IM862 | Seems to have superior TTP |
No active antineoplastic treatment.
References
- AMC 013: Noy A, Scadden DT, Lee J, Dezube BJ, Aboulafia D, Tulpule A, Walmsley S, Gill P; AIDS Malignancy Consortium. Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team. J Clin Oncol. 2005 Feb 10;23(5):990-8. Epub 2004 Dec 14. link to original article PubMed